Insatiable Acquisition Machine Accenture – Buyback Wednesdays

 

Based in Dublin, Ireland, Accenture plc (ACN) is an Irish-American digital consultant, specializing in information technology services and consulting. It helps businesses achieve their strategic objectives through digital transformation with operations across 49 countries

Accenture’s current clients include 91 of the Fortune Global 100 and more than three-quarters of the Fortune Global 500. Accenture has a larger presence in Europe and the United States compared to other regions. As of 2022, Accenture is considered the largest consulting firm in the world by number of employees with about 733,000 employees worldwide.

Read More Info @ https://www.insidearbitrage.com/2023/10/insatiable-acquisition-machine-accenture-buyback-wednesdays/

Accenture has been consistently outperforming the S&P 500 over the last 10 years. The share price is up 15.6% over the last year and 13.3% this year.

On September 28, 2023, the board of the company authorized an additional $4 billion share repurchase program that represents around 2% of its market cap at announcement.

Key Insights

  • Accenture is an insatiable acquisition machine, acquiring 165 companies over the last five years and yet maintaining a pristine balance sheet with nearly $9 billion in net cash.
  • The company has a massive employee count of 733,000 and a wide geographic footprint across 49 countries.
  • Offsetting dilution caused by stock-based compensations seems to be the major reason for the huge share repurchases initiated by the company.
  • The company’s recent allocation of $3 billion for AI initiatives is substantial.
  • A decline of 10% in new bookings in Q4 FY2023 ended August 2023 reflects poorly on future growth prospects

Get access to premium merger arbitrage content. Subscribe today

Acquisitions

Accenture has pursued an aggressive acquisition strategy to broaden its service offerings, having acquired a total of 165 companies in the past five years. While many of these acquisitions involve smaller firms, their collective contributions have been substantial. In 2022, the company made 25 acquisitions worldwide, including Barcelona-based Alfa Consulting, Argentina-based Ergo, Brussels-based Greenfish, and Minnesota-based The Stable.

Artificial Intelligence

Accenture is rapidly taking a leadership position in AI. Last quarter, the company booked 100 AI projects with roughly $100 million in sales. Demand accelerated in fiscal Q4 2023 with another approximately $200 million in AI sales, bringing the total to over $300 million for the year.

Accenture has also embedded AI across its service delivery approach, driving efficiency and accelerating value for thousands of clients through its market leading platforms such as myWizard, SynOps, and MyNav.

Dividends

Accenture has consistently paid dividends without interruption and has steadily increased them since 2005. It has increased its quarterly dividend from $0.8 per share in October 2019 to $1.12 per share in August 2023.

In August 2023, the company paid its fourth quarter cash dividend of $1.12 per share for a total of $706 million and also increased its next quarterly dividend to $1.29 per share to be paid to shareholders on record as of October 11, 2023, a 15% increase over the previous quarter.

A forward dividend yield of 1.67% may seem small, but it is important to note that with a payout ratio of 41.04%, the dividend is sustainable, stable, and growing, with room for future increases.

Profitability

The company has maintained fairly stable gross and net margins over the past five years. Its current net margin is 10.72%, and the return on equity for the trailing twelve months is an impressive 28.75%, both significantly exceeding the sector’s median figures.

Capital Allocation 

In 2022, Accenture deployed over $2.5 billion across 25 acquisitions, $1.3 billion in R&D assets, platforms, and industry solutions, and $1.1 billion invested in the training and development of its people. In the fourth quarter of 2023, Accenture repurchased 3.2 million shares for $1 billion at an average price of $312.35 per share.

Share Repurchases

Accenture has announced share repurchases consecutively for three years, announcing $3 billion in additional buybacks each in 2021 and 2022, representing 1.3% and 1.8% of their market caps at announcement respectively. During the fourth quarter of fiscal 2021, the company purchased 2.9 million shares under this program for an aggregate price of $891 million.

However, the shares outstanding count has shown only a slight decline in 4 years, reducing from 649.3 million in May 2019 to 638.7 million in May 2023, indicating that the company has retired only 1.63% of its outstanding shares over the last 4 years. This suggests that these share repurchases are mostly initiated to offset the dilution caused by stock-based compensations offered by the company.

Valuation

Accenture appears overvalued with a forward P/E of 26.14 and forward EV/EBITDA of 15, well above the average sector median. This higher valuation suggests that the stock is relatively expensive, underscoring the market’s strong confidence in the company’s prospects.

Balance Sheet and Cash Flow

Accenture has a strong balance sheet with no debt at all. Instead, it had net cash of $8.9 billion as of August 2023, an increase of $1.06 billion from last year. The value of its assets is nearly twice that of its liabilities, and its short-term assets exceed short-term liabilities. Its debt-free balance sheet is surprising given the number of acquisitions made by the company, especially in the last 5 years.

Comments

Post a Comment

Popular posts from this blog

Darden's Bold Move: Acquiring Chuy's for a Flavorful Future

  In the latest shake-up in the restaurant industry, Darden Restaurants, Inc. has announced its acquisition of Chuy's Holdings, Inc . This merger is set to create a powerhouse in the casual dining sector, bringing together two beloved brands under one corporate roof. Here’s what you need to know about this exciting development. Chuy’s Holdings Inc. ( CHUY ):  $37.08 Market Cap:  $643.38 M Deal Size:  $605 M Back in 2014, a heated battle between Darden Restaurants  (DRI)  and the activist hedge fund Starboard Value brought to light some surprising inefficiencies within Darden’s flagship chain, Olive Garden. In an attempt to win control of Darden’s board, Starboard pointed out not only the wastefulness of unlimited breadsticks at Olive Garden but also its puzzling decision to stop salting its pasta water as “adding salt to the boiling water could jeopardize warranties on pots”. These small yet significant details became symbols of the broader issues w...
Read more

Inside the $5.1 Billion Deal: Sixth Street’s Strategic Acquisition of Enstar Group

  Enstar Group Limited (NASDAQ: ESGR) recently became the focal point of investor discussions as Sixth Street Partners announced its acquisition for approximately $5.1 billion. This acquisition has piqued interest not only due to its substantial value but also because of the involvement of notable figures such as former Treasury Secretary Steven Mnuchin and billionaire investor J. Christopher Flowers. Deal Overview In a market where mergers and acquisitions often make headlines, Sixth Street’s acquisition of Enstar Group stands out. Enstar, an insurer with a market cap of $4.97 billion, caught the eye of Sixth Street, an investment firm that already held a 4% stake in the company. The terms of the agreement are straightforward: Sixth Street will pay Enstar shareholders $338.00 in cash per ordinary share. This price represents a 2.96% discount from Enstar's last closing price of $326.91 and offers a 5.5% premium over the 30-day average price. Market Reaction Following the a...
Read more

Strategic Biopharma Merger: Pharmacosmos to Acquire G1 Therapeutics in $405M Deal

  In the ever-evolving landscape of the biopharmaceutical industry, strategic acquisitions and mergers are critical for companies looking to bolster their portfolios and expand their global reach. Last week, we witnessed a noteworthy development as G1 Therapeutics Inc. (NASDAQ: GTHX) became the latest target in a high-profile acquisition by Pharmacosmos A/S, a Denmark-based company renowned for its expertise in carbohydrate chemistry and treatments for iron deficiency and anemia. Read More Info @ https://www.insidearbitrage.com/2024/08/g1-therapeutics-attracts-a-danish-suitor-merger-arbitrage-mondays/ The Deal in Detail Pharmacosmos, through its U.S. subsidiary Pharmacosmos Therapeutics Inc., has entered into a definitive merger agreement to acquire G1 Therapeutics for a total deal size of approximately $405 million. This transaction represents a significant premium over G1's market value, offering $7.15 per share in cash, which is a substantial 68.24% premium over G1’s las...
Read more